GLPwatch
Papers (12034)
Page 169 of 201, ranked by citation count.
- Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.
- A multi-organ atlas of microcirculatory signatures for systemic profiling of diabetic and therapeutic states.
- Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
- Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
- Semaglutide in the spotlight: weighing benefits against rising concerns.
- Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
- Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.
- Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.
- GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
- Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.
- Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.
- Semaglutide in weight management.
- Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Discontinuation of Tirzepatide and Semaglutide Prior to Gastric Sleeve Surgery: Clinical Considerations and Guidelines.
- Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury.
- Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
- Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
- [Comments on current guidelines of type 2 diabetes mellitus treatment].
- Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
- Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.
- Peripheral neuropathic symptoms with GLP-1 receptor agonists: Insights from a large real-world cohort.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.
- Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.
- Tirzepatide for Heart Failure and Obesity.
- The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats.
- Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide.
- Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.
- Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.
- Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
- Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y<sub>2</sub> receptor tri-agonist for obesity and type 2 diabetes.
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]
- Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.
- Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.
- Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity.
- Semaglutide and Cardiovascular Outcomes.
- Effect of nano extracts of olea europaea leaves, ficus carica and liraglutide in lipidemic liver of type 2 diabetic rat model.
- Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months).
- Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk".
- Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
- Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Reply.
- Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.
- The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.
- Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.
- Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
- GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.
- Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.
- Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case.
- The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.
- Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations.
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.
- Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway.
- Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
- Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
- Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.
- [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].